固相生物科学公司收到STTR二期赠款项目的标题为:药物发现铅优化芯片的发展。他们奖资助在2009年美国复苏与再投资法案和他们的项目将解决饲料复合铅优化芯片的进一步发展和商业化(Multizyme芯片)高通量代铅化合物的类似物加上细胞筛选生物活性的快速识别衍生品。这种能力直接影响药物发现的一个关键瓶颈;即铅化合物的高效优化与最优开发药物药理性质。固相生物科学公司提出把六个生物催化与生物活性化合物的药理筛选提供快速识别特异性的目标,这是一个新的范例铅优化。此外,Multizyme芯片平台将在相关行业,适合领导优化雷竞技推荐码怎么获得包括农用化学品、化妆品和药妆品。固相技术将因此提高竞争力和效率的制药、化妆品、化学工业,将作为丰富的新的和改进的商业产品。这项研究的广泛影响是固相生物科学的进步将实现向创造更好、更安全的药物,这些药物降低开发成本,提高制药行业的整体效率。固相将生成Multizyme芯片供制药和生物技术公司,以促进他们的购买铅优化程序,特别是那些涉及天然product-derived和复杂的合成小分子线索。低温贮藏技术开发的第二阶段将使芯片的销售和chip-handling设备生产阶段,并将允许固相技术平台的无缝渗透进入该公司的目标市场。雷竞技推荐码怎么获得 Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

NeuroGenomeX药物发现公司发展新的大脑和神经系统疾病的治疗。当前NeuroGenomeX发现程序集中在治疗癫痫症和创伤性脑损伤的靶区。NeuroGenomeX推进其领导的候选药物,2-deoxy-D-glucose (2 dg),作为一个抗惊厥的阻止癫痫发作和癫痫的有利影响与不利的长期后果。2 dg也已经显示出良好的治疗创伤性脑损伤的神经保护作用在动物模型(创伤性脑损伤)。

SynDevRx已开发出一项技术,增加了活动和安全使用共轭小分子药物的技术。公司的技术提高药物的治疗指数由集中活动的疾病。它为小分子提供可预测的和可靠的物理特性,可以加快开发时间和降低成本,同时提高PK概要文件。SynDevRx首席药物候选人有关- 7320肿瘤市场目标,和抑制MetAP2——一种酶,独立研究显示肿瘤生长的关键,扩散和转移。

Konova提供抗肥胖药物开发

Allozyne是一种蛋白质优化公司致力于改善生物疗法来治疗的发展尚未被满足的医疗需求的多个领域。Allozyne的两个技术平台使氨基酸类似的公司,在雷竞技推荐码怎么获得任何指定的位置,到现有生物制剂导致改善疗效、耐受性和药理学。

Optimata有限公司是一个私营企业以科学为基础的跨学科公司从事biosimulation技术优化药物治疗协议。Optimata与制药和生物技术公司合作伙伴开发有效的疾病通过模拟疾病新的治疗方法流程。这个旨在减少投放市场的时间和开发成本,同时提高竞争力的新开发药物。